La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Bioxyne Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Bioxyne has a total shareholder equity of A$2.7M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$4.7M and A$2.1M respectively.

Informazioni chiave

Rapporto debito/patrimonio netto

AU$0

Debito

Indice di copertura degli interessi	n/a
Contanti	AU$1.53m
Patrimonio netto	AU$2.67m
Totale passività	AU$2.06m
Totale attività	AU$4.74m

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: BXN's short term assets (A$4.7M) exceed its short term liabilities (A$2.1M).

Passività a lungo termine: BXN has no long term liabilities.

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: BXN is debt free.

Riduzione del debito: BXN had no debt 5 years ago.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: BXN has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.

Previsione Cash Runway: BXN is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.

Bioxyne Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 1.45 million.

Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 1.45 million.

New major risk - Market cap size

Bioxyne Limited Announces Retirement of N H Chua as Director

Bioxyne Limited, Annual General Meeting, Nov 17, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

Full year 2023 earnings released: EPS: AU$0.002 (vs AU$0 in FY 2022)

New minor risk - Financial data availability

Bioxyne Limited Appoints Jason Hine as Director

Bioxyne Limited (ASX:BXN) completed the acquisition of Breathe Life Sciences Pty Ltd.

First half 2023 earnings released

Bioxyne Limited (ASX:BXN) entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million.

Bioxyne Limited Announces Joining of Mr. Sam Watson the Board as Joint Chief Executive Officer

No independent directors

Paramount Star Investments Limited reached agreement to acquire 49% of Direct Selling Business of Bioxyne Limited from Bioxyne Limited (ASX:BXN) for $1 million.

Bioxyne Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2021)

Full year 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2021)

No independent directors

Bioxyne Limited Announces Board Changes

No independent directors

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)

Full year earnings released - AU$0.00093 loss per share

Full year earnings released - AU$0.0009 loss per share

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane